Abstract: TH-PO833
Effects of Curcumin Supplementation on mRNA Expression of NLRP3 Inflammasome, IL-1β, and NF-κB in Hemodialysis Patients
Session Information
- Health Maintenance, Nutrition, Metabolism
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Health Maintenance‚ Nutrition‚ and Metabolism
- 1400 Health Maintenance‚ Nutrition‚ and Metabolism
Authors
- Mafra, Denise, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Alvarenga, Livia De almeida, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Ribeiro-Alves, Marcelo, Fundacao Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
- Cardozo, Ludmila Fmf, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
Background
Chronic Kidney Disease (CKD) patients have many complications associated with inflammation and oxidative stress. Inflammasomes are multimeric protein complexes that can be activated by the nuclear factor kappa-B (NF-κB). When the NLRP3 is activated, pro-Interleukin 1β (IL-1β) is cleavaged to IL-1β, inducing the inflammatory response. Curcumin may mitigate the inflammatory process.
Methods
Thirty-one patients with CKD on HD were randomized into two groups: “Curcumin” and “Control.” The curcumin group received 100 mL of orange juice with 12 g of carrots and 2.5 g of turmeric three times a week for three months. The control group received the juice with the same composition (without curcumin). The mRNA expression of NF-κB, NLRP3, and IL-1β was measured by real-time polymerase chain reaction (RT-qPCR) on PBMC.
Results
Twenty-eight patients concluded the study, 14 patients in the control group [50% men, 51.5 (IQR=15.5) years, HD time 36 (IQR=38.75) months], and 14 patients in the curcumin group [50% men, 56.5 (IQR=20) years, HD time 45 (IQR=85) months]. After three months of supplementation with curcumin, the patients showed a significant reduction in mRNA expression of IL-1β (p=0.05) (Figure 1).
Conclusion
Curcumin supplementation showed to mitigate inflammation in CKD patients on HD by decreasing mRNA IL-1β expression.
Figure 1. Comparison of mRNA of the factors of evolution of the inflammatory pathway before and after three months of intervention
Funding
- Government Support – Non-U.S.